Market Overview

XTL Biopharma Buys Stake in Proteologics from Teva

Share:
Related TEVA
Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine Study Meeting Primary and Secondary Endpoints
Stocks Hitting 52-Week Highs
FDA imposes limits on testosterone drugs and labeling changes to warn of potential heart risks (Seeking Alpha)

XTL Biopharmaceuticals Ltd. announced on November 21^st that it has acquired 4,620,356 shares, of Proteologics Ltd., from Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) in consideration for an amount of approximately NIS 6.5 million, which represents an amount of NIS 1.405 per Share (approximately 22% premium). The Shares represent all of Teva's shares in Proteologics and represent approximately 31.35% of Proteologics issued and outstanding share capital.

Posted-In: News Asset Sales

 

Related Articles (TEVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→